NOT FOR DISTRIBUTION
Header cover image

Market Cap

€15.7b

Last Updated

2021/05/01 19:22 UTC

Data Sources

Company Financials +

Executive Summary

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. More Details


Snowflake Analysis

Solid track record with adequate balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has Eurofins Scientific's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ERF is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ERF's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-4.6%

ERF

-2.4%

FR Life Sciences

1.1%

FR Market


1 Year Return

63.1%

ERF

52.3%

FR Life Sciences

42.2%

FR Market

Return vs Industry: ERF exceeded the French Life Sciences industry which returned 60.4% over the past year.

Return vs Market: ERF exceeded the French Market which returned 39.6% over the past year.


Shareholder returns

ERFIndustryMarket
7 Day-4.6%-2.4%1.1%
30 Day-1.2%4.6%4.3%
90 Day4.0%2.9%12.0%
1 Year63.1%63.1%52.7%52.3%45.5%42.2%
3 Year85.9%83.7%156.9%152.5%28.5%18.2%
5 Year162.8%157.4%307.7%283.5%86.4%59.8%

Long-Term Price Volatility Vs. Market

How volatile is Eurofins Scientific's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eurofins Scientific undervalued compared to its fair value and its price relative to the market?

30.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ERF (€82.35) is trading above our estimate of fair value (€76.54)

Significantly Below Fair Value: ERF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ERF is good value based on its PE Ratio (30.3x) compared to the XE Life Sciences industry average (58.2x).

PE vs Market: ERF is poor value based on its PE Ratio (30.3x) compared to the French market (24.8x).


Price to Earnings Growth Ratio

PEG Ratio: ERF is poor value based on its PEG Ratio (25.7x)


Price to Book Ratio

PB vs Industry: ERF is good value based on its PB Ratio (4.3x) compared to the XE Life Sciences industry average (6.3x).


Future Growth

How is Eurofins Scientific forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ERF's forecast earnings growth (1.2% per year) is above the savings rate (0.4%).

Earnings vs Market: ERF's earnings (1.2% per year) are forecast to grow slower than the French market (21.5% per year).

High Growth Earnings: ERF's earnings are forecast to grow, but not significantly.

Revenue vs Market: ERF's revenue (3.4% per year) is forecast to grow slower than the French market (7.2% per year).

High Growth Revenue: ERF's revenue (3.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ERF's Return on Equity is forecast to be low in 3 years time (12.5%).


Past Performance

How has Eurofins Scientific performed over the past 5 years?

25.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ERF has high quality earnings.

Growing Profit Margin: ERF's current net profit margins (9.3%) are higher than last year (3.2%).


Past Earnings Growth Analysis

Earnings Trend: ERF's earnings have grown significantly by 25.5% per year over the past 5 years.

Accelerating Growth: ERF's earnings growth over the past year (246.7%) exceeds its 5-year average (25.5% per year).

Earnings vs Industry: ERF earnings growth over the past year (246.7%) exceeded the Life Sciences industry 42.8%.


Return on Equity

High ROE: ERF's Return on Equity (14.5%) is considered low.


Financial Health

How is Eurofins Scientific's financial position?


Financial Position Analysis

Short Term Liabilities: ERF's short term assets (€2.5B) exceed its short term liabilities (€1.7B).

Long Term Liabilities: ERF's short term assets (€2.5B) do not cover its long term liabilities (€3.2B).


Debt to Equity History and Analysis

Debt Level: ERF's debt to equity ratio (70.5%) is considered high.

Reducing Debt: ERF's debt to equity ratio has reduced from 156.5% to 70.5% over the past 5 years.

Debt Coverage: ERF's debt is well covered by operating cash flow (46.7%).

Interest Coverage: ERF's interest payments on its debt are well covered by EBIT (8.8x coverage).


Balance Sheet


Dividend

What is Eurofins Scientific current dividend yield, its reliability and sustainability?

0.83%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ERF's dividend (0.83%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.29%).

High Dividend: ERF's dividend (0.83%) is low compared to the top 25% of dividend payers in the French market (4.07%).


Stability and Growth of Payments

Stable Dividend: ERF's dividends per share have been stable in the past 10 years.

Growing Dividend: ERF's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (25.1%), ERF's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ERF's dividends in 3 years are forecast to be well covered by earnings (24.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.1yrs

Average board tenure


CEO

Gilles Martin (57 yo)

no data

Tenure

€1,189,214

Compensation

Dr. Gilles G. Martin, Ph.D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He ...


CEO Compensation Analysis

Compensation vs Market: Gilles's total compensation ($USD1.43M) is below average for companies of similar size in the French market ($USD3.87M).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: ERF's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.6%.


Top Shareholders

Company Information

Eurofins Scientific SE's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eurofins Scientific SE
  • Ticker: ERF
  • Exchange: ENXTPA
  • Founded: 1987
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €15.738b
  • Shares outstanding: 191.11m
  • Website: https://www.eurofins.com

Number of Employees


Location

  • Eurofins Scientific SE
  • 23 Val Fleuri
  • Luxembourg City
  • 1526
  • Luxembourg

Listings


Biography

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/01 19:22
End of Day Share Price2021/04/30 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.